公司資料
Quest Diagnostics 股價、新聞與催化劑
- 股票代碼:
- DGX
- 交易所:
- NYSE
- 產業:
- MedTech
- 所在地:
- Secaucus, New Jersey
股票表現
235.52 USD (+0.48%)
收盤價
最後更新: 2026年8月17日
21.4B USD
市值
股價為何變動
As of Aug 17, 2026, DGX closed up 0.48% at $235.52. No new same-company headline was identified in the current news window.
公司概覽
Diagnostic Information Services Leader
Quest Diagnostics provides laboratory testing and diagnostic insights to physicians, hospitals, consumers, and population-health partners. Its core value lies in converting testing data into information that supports disease detection, treatment decisions, and health management.
Consumer Access Channels
Quest is expanding access through questhealth.com, consumer-health services, wearable-device partnerships, and wellness programs. These channels allow individuals and employers to use the company’s laboratory network outside traditional physician-ordered testing workflows.
Advanced Diagnostics
The Advanced Diagnostics portfolio includes blood-based Alzheimer’s testing and assays in cardiometabolic disease, endocrinology, and liver fibrosis. These higher-value tests extend Quest into areas requiring specialized interpretation and clinical decision support.
Oncology Testing and Digital Integration
Quest received New York State approval for the Haystack minimal residual disease test and is piloting molecular-testing integration through Flatiron Health’s OncoEMR Molecular Profiling Integration platform. These initiatives extend the company beyond traditional laboratory services into precision oncology and embedded clinical workflows.
National Laboratory Network
Quest’s scale is built on a broad network of laboratories, patient service centers, logistics, and relationships with physicians and health systems. This infrastructure supports high-volume routine testing while providing a distribution channel for newly introduced advanced diagnostics.
未來催化劑
- Quest Diagnostics should be watched for advanced-diagnostics mix, volume trends, and any acquisition or network-expansion step. The next update will help show whether the company is moving from promise to a more de-risked stage of execution. Investors will care less about the label than about whether the platform can keep producing credible next steps.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。